RadNet Inc (NASDAQ:RDNT) said Monday that it has reached an agreement to purchase Gleamer, a Paris-based radiology artificial intelligence company, in an all-cash transaction valued at as much as 230 million euros, equivalent to $270 million. The announcement came ahead of both companies presenting their combined pipeline at the European Congress of Radiology in Vienna this week.
In a statement, RadNet said the acquisition will expand its DeepHealth business into what it expects will be the world’s largest provider of clinical radiology AI, serving more than 2,700 customers across over 50 countries. The company described Gleamer as a firm founded in 2017 whose AI offerings span more than 25 clinical uses.
Gleamer projects it will generate $30 million in annual recurring revenue in 2026, a figure cited by RadNet in outlining the transaction’s commercial backdrop. RadNet also said Gleamer’s technology is designed to help address shortages of radiologists and to produce efficiency gains and cost savings for providers, with those benefits expected to materialize by the third quarter of 2026.
The market reacted quickly to the deal: RadNet shares were up about 3% in premarket trading, changing hands at $71.91 on Monday, according to the company announcement. RadNet framed the acquisition as a way to broaden the geographical reach and clinical breadth of DeepHealth while scaling the combined product pipeline.
Summary of the transaction
- Acquirer: RadNet Inc, a U.S. imaging company.
- Target: Gleamer, a French radiology AI firm founded in 2017.
- Consideration: All-cash deal valued up to 230 million euros ($270 million).
- Business impact: DeepHealth expected to serve 2,700+ customers across more than 50 countries.
Market context and timing
Both companies plan to showcase their combined product roadmap at the European Congress of Radiology in Vienna this week. RadNet highlighted the acquisition as bolstering its clinical AI capabilities and accelerating deployment of algorithms that cover a wide range of radiology use cases.
RadNet indicated that operational efficiencies and cost savings tied to the integration of Gleamer’s technology are expected to be realized by the third quarter of 2026. The announcement included Gleamer’s internal projection of $30 million in annual recurring revenue in 2026 and emphasized the breadth of clinical applications supported by the French firm’s AI tools.